

Managing Elevated LDL-C Levels to Reduce ASCVD Risk: Primary and Secondary Prevention

USF Health **Rockpointe**[®]

powered by CEA

Local/Regional Live and Virtual Meeting Series
Kansas Academy of Family Physicians

Date: Wednesday, June 28, 2023


Time: 12:15 PM - 1:15 PM CT

For full accreditation information and to register, visit:

www.clinicaloptions.com/Lipids2023

Suggested Browsers: Apple Safari, Google Chrome, or Mozilla Firefox

PROGRAM FACULTY



Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC

Director of Women's Cardiovascular Health Research

Associate Director of Preventive Cardiology


Associate Professor of Medicine & Epidemiology

Division of Cardiology

Johns Hopkins University School of Medicine

Baltimore, Maryland

Co-Editor in Chief, American Journal of Preventive Cardiology



Margo B. Minissian, PhD, ACNP, FAHA, FNLA

Executive Director, Geri and Richard Brawerman Nursing Institute

Simms/Mann Family Foundation Endowed Chair in Nurse Education, Innovation and Research

Assistant Professor, Cardiology

Cedars-Sinai

Los Angeles, California

PROGRAM OVERVIEW

Kansas Academy of Family Physicians cordially invites you to attend a CME/CE-certified presentation titled, **“Managing Elevated LDL-C Levels to Reduce ASCVD Risk: Primary and Secondary Prevention.”** This activity will provide primary care providers with the necessary knowledge to identify and treat patients who would benefit from ASCVD risk reduction. Learn about the latest treatment recommendations, including nonstatin therapies, LDL-C goals, and best practices in developing a personalized multidisciplinary treatment plan to optimize patient care.

LEARNING OBJECTIVES

- Assess the efficacy, safety, and mechanism of action of nonstatin agents approved to manage LDL-C levels
- Devise individualized evidence-based primary prevention plans for patients with elevated LDL-C levels
- Develop personalized strategies for secondary prevention for patients with elevated LDL-C levels using evidence-based guidelines
- Escalate treatment of elevated LDL-C levels by incorporating approved nonstatin agents when statins alone do not achieve 2018 blood cholesterol guideline goals

ACCREDITATION STATEMENT: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of USF Health and Rockpointe. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION STATEMENT: USF Health designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC RECOGNITION STATEMENT: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.



AMERICAN ASSOCIATION OF NURSE PRACTITIONERS (AANP) CREDIT DESIGNATION

This activity is approved for 1.0 contact hour(s) of continuing education (which includes 1.0 hour(s) of pharmacology) by the American Association of Nurse Practitioners®. Activity ID# 23036015. This activity was planned in accordance with AANP Accreditation Standards and Policies.

AMERICAN ASSOCIATION OF PHYSICIAN ASSOCIATES (AAPA) CREDIT DESIGNATION

This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Participants should only claim credit commensurate with the extent of their participation. Approval is valid from 4/4/2023 to 9/4/2024. AAPA reference number: CME-209116.

AAFP CREDIT DESIGNATION STATEMENT

The AAFP has reviewed Managing Elevated LDL-C Levels to Reduce ASCVD Risk: Primary and Secondary Prevention, and deemed it acceptable for AAFP credit. Term of approval is from 04/04/2023 to 08/01/2023. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

FEE AND RECEIVING CME CREDIT/MOC POINTS: There is no fee for this activity. To receive credit, participants must register, view the live CME/MOC activity in its entirety, and then complete the posttest, with a score of 70% or better, and evaluation. The estimated time for completion of this activity is 1 hour. To receive a certificate, participants must demonstrate mastery of the presented material via the posttest. Participant is allowed to take the posttest multiple times.

Disclosures will be made known to participants before the activity.

Jointly provided by USF Health and Rockpointe, in partnership with Clinical Care Options, LLC
Supported by an educational grant from Novartis Pharmaceuticals Corporation.